INS and diabetes mellitus: The oral hypoglycaemics include sulfonylureas, biguanides, cotransporter inhibitors of sodium-glucose, inhibitors of DP-4, glucagon like peptide–1 agonist, thiazolidinedione, meglitinide, inhibitors of α-glucosidase, and glucose-dependent insulinotropic polypeptide agonists, varieties of insulins, amylinomimetics, bile acid sequestrants, dopamine agonists (Yang et al. 2023; Corcoran and Jacobs 2023; Di Magno et al. 2022; Guo et al. 2020; Wilcox 2020; Chen et al. 2018; Chaudhury et al. 2017; Standards of Medical Care in Diabetes 2016; Chamberlain et al. 2016).